Emma’s Fight for FA Drug Access

Emma O’Shea, living with Friedreich’s Ataxia, is fighting for access to Skyclarys — a breakthrough drug that’s shown a 55% slowdown in disease progression — yet Ireland, where the drug is even made, still hasn’t covered its cost. Despite promising improvements in coordination and quality of life for patients, bureaucratic hurdles and high prices have stalled reimbursement, leaving 200 Irish FA patients without hope. Emma’s brother died from the disease, and she’s determined to ensure others don’t face the same fate — especially as the long-term care costs of FA are staggering. Advocates are pushing hard, but time is running out. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5fc67ff3672b7955